Regulatory November date set for FDA decision on Sanofi’s Gaucher drug PharmaphorumThe FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.Rare DiseaseRead full story pharminent May 28, 2026 (Last updated: May 30, 2026) Pharmaphorum The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November. Rare Disease Read full story Post navigation Previous: Kailera’s three-pronged obesity shot shows promise in early trialNext: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
